Lantern Pharma Inc. has entered into a strategic artificial intelligence (AI)-driven collaboration with Oregon Therapeutics SAS to optimize the development of Oregon’s first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate XCE-853 in novel and targeted cancer indications.

Cerevance Inc. has announced the achievement of the first milestone in its research collaboration with Merck & Co.

Repertoire Immune Medicines Inc. has entered a multiyear strategic collaboration with Bristol Myers Squibb Co. (BMS) to develop tolerizing vaccines for up to three autoimmune diseases.

Peptidream Inc. and Novartis Pharma AG have expanded their peptide-drug conjugate discovery collaboration announced in 2019, adding additional peptide radioligand therapies and other programs.

Alligator Bioscience AB reported that Orion Corp. has selected the lead bispecific antibodies from the companies’ second development program, and is exercising its option to develop these molecules under the existing 2021 research collaboration and license agreement.

Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Prism Biolab Co. Ltd. to generate novel oncology drug candidates.

Ochre Bio Ltd. has established a partnership with Boehringer Ingelheim Pharma GmbH & Co. KG focused on the discovery and development of novel first-in-class regenerative treatments for chronic liver diseases, such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.

Ipsen SA and Skyhawk Therapeutics Inc. have entered an exclusive worldwide collaboration to discover and develop small molecules that modulate RNA for rare neurological diseases. Skyhawk has a unique platform that accelerates building RNA-targeting small molecules across several therapeutic areas.

Curevac NV and The University of Texas MD Anderson Cancer Center have entered into a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

Spikimm SAS has signed an exclusive collaboration and license option agreement with SATT Conectus Alsace SAS for monoclonal antibodies targeting the BK virus. Reactivation of the BK virus (BKV) in patients receiving kidney transplant, bone marrow or stem cell grafts has potential serious consequences.